Indeed, the pharmacological inhibition of GSK-3 has been reported to upregulate both Myc and β-catenin protein levels, thus enhancing Myc-mediated apoptosis in neuroblastoma and KRAS-dependent cellular models [140,141]. The gene discussed is MYC; the disease is neuroblastoma.